Natalie Haslacher's Colleagues at XClinical GmbH
Natalie Haslacher's Contact Details
N/A
XClinical GmbH
Natalie Haslacher's Company Details
XClinical is an international EDC vendor headquartered in Europe, founded in 2002. Our software solutions and technical services accelerate clinical trials worldwide. We are focused on specific requirements and provide our cusotmers with the flexibility to adapt to ever-changing needs. Clinical has over 15 years of experience with EDC software. Our employees are experts in clinical research, project management, software development, data privacy Manage the lifecycle of a clinical study from eCRF setup to data sets ready for submission with Marvin, XClinical's all-in-one, user-friendly eClinical software. Marvin helps CROs, biopharmaceutical, and medical device corporations accelerate study setup and execution, save time, and improve data quality. Meet Marvin, Your All-In-One eClinical Software Platform. Data is one of the greatest assets for clinical trial teams, yet managing that data remains a challenge. Disparate systems and mismatching data formats are continuing to hold organizations back. XClinical helps clinical study sponsors and CROs overcome these challenges and harness the power of their data to better manage clinical trials. Marvin, XClinical's electronic all-in-one solution – provides a range of integrated modules in one platform, enabling the seamless flow of data to improve data quality. These modules include EDC, study build, data collection, IWRS and drug management, WebPRO, SDTM tabulation, MedDRA and WHODrug Coding, reporting, and CTMS. Everything is built to CDISC standards and improves access to data by delivering these modules on any web browser, in any language. Update January 21, 2021: XClinical, announced a merger with France-based Carenity, a social platform supporting patients and caregivers worldwide, and Fortress Medical Systems, the US-based vendor of Clindex®, an integrated CTMS and EDC system. All three companies are long-established, leading providers in their respective markets.